Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more
Handok - Asset Resilience Ratio
Handok (002390) has an Asset Resilience Ratio of 0.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Handok's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Handok's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩7.99 Billion | 0.99% |
| Total Liquid Assets | ₩7.99 Billion | 0.99% |
Asset Resilience Insights
- Limited Liquidity: Handok maintains only 0.99% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Handok Industry Peers by Asset Resilience Ratio
Compare Handok's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Handok (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Handok.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.38% | ₩3.00 Billion | ₩788.56 Billion | -0.06pp |
| 2023-12-31 | 0.44% | ₩3.50 Billion | ₩790.34 Billion | +0.10pp |
| 2022-12-31 | 0.34% | ₩3.00 Billion | ₩871.11 Billion | -0.25pp |
| 2021-12-31 | 0.59% | ₩5.00 Billion | ₩841.56 Billion | -0.63pp |
| 2020-12-31 | 1.22% | ₩10.00 Billion | ₩818.93 Billion | -0.66pp |
| 2019-12-31 | 1.89% | ₩14.12 Billion | ₩748.67 Billion | +1.49pp |
| 2018-12-31 | 0.40% | ₩2.61 Billion | ₩652.62 Billion | +0.38pp |
| 2017-12-31 | 0.02% | ₩113.22 Million | ₩639.35 Billion | -- |